1. �й�ҽѧ��ѧԺ����Э��ҽѧԺƤ�����о���
2. �Ͼ� �й�ҽѧ��ѧԺ����Э��ҽѧԺƤ�����о���

��ժҪ�� άA����ҩ����һ��ά����A��������е���ϸ����ֳ���ֻ����ٽ����������ò���Ӱ����������Ӧ����Ӧ����Ƥ��Tϸ���ܰ������������ж��꣬��Чȷ�С�άA����ҩ������ѧ���û�����Ҫ��ͨ����άA�������άA��X�����ϣ�ת¼��������Ӻ�ת¼�������Ӳ��룬�յ�����ת¼��άA������ѡ�����άA��X����ѡ�������Ƥ��Tϸ���ܰ�������Ч��������������Ч�����ԡ�άA����ҩ�ﳣ����ơ������ؼ������������Ƽ����ϣ��������Ʒ��ѳ�Ϊ����Ƥ��Tϸ���ܰ�����Ӧ�õ���Ҫ��ʽ��άA����ҩ��IJ�����Ӧ��Ҫ�����ڶԸι��ܡ�Ѫ֬����״�ټ���ˮƽ����ϸ������ֳϵͳ��Ӱ�죬������Ҫ����ΪƤ���̼���Ӧ��

Yang Hua, Ma Pengcheng Pharmacal Research Laboratory, Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China Corresponding author: Ma Pengcheng, Email: mpc815@163.com ��Abstract�� Retinoids are a kind of derivatives of vitamin A modulating cell proliferation, differentiation, apoptosis and altering the immune response. They have been used for years in the treatment of cutaneous T?cell lymphomas ��CTCL�� with definite efficacy. The biological mechanism of action of retinoids depends on their binding to retinoic acid receptor ��RAR�� and retinoid X receptor ��RXR��, and the participation of coactivator ��CoA�� and corepressor ��CoR��, following by the induction of gene transcription. Both RAR? and RXR?selective agents are effective for the treatment of CTCL, but combination therapies are better. Retinoids are often used in combination with phototherapy, interferon and other immunosuppressive agents, and combination therapies have become the main therapy for CTCL. Adverse reactions to oral retinoids mainly include impacts on liver function, blood lipid level, thyroid hormone level, white blood cells and reproductive system, and topical retinoids may cause irritant skin reactions.